Nanexa AB (40M) Price & Analysis

0 Followers

40M Stock Chart & Stats

€0.25

>-€0.01(-2.14%)

At close: Jan 08 4:00 PM EST

€0.25

>-€0.01(-2.14%)

Day’s Range― - ―

52-Week Range€0.12 - €1.28

Previous CloseN/A

Volume0.00

Average Volume (3M)4.96K

Market Cap

€145.79M

Enterprise Value€632.73

Total Cash (Recent Filing)€52.56M

Total Debt (Recent Filing)€795.00K

Price to Earnings (P/E)―

Beta1.33

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding164,585,050

10 Day Avg. Volume14,759

30 Day Avg. Volume4,956

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)6.83

Price to Sales (P/S)19.19

P/FCF Ratio-26.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€10.36M

Bulls Say, Bears Say

Bulls Say

PharmaShell PlatformThe PharmaShell platform addresses an important pharmaceutical development need by targeting sustained drug release and more convenient dosing. If technical development succeeds, this capability could support differentiated injectable medicines and create durable partnering opportunities across multiple drug programs.

Partnering-based MonetizationA partnering and licensing model can let Nanexa monetize its technology without bearing the full cost of commercializing every medicine itself. Upfront payments, development milestones and royalties provide several potential revenue streams as partner programs progress.

Low Financial LeverageVery low leverage gives Nanexa greater financial flexibility than a heavily indebted development company. Limited debt exposure reduces fixed financing pressure and leaves more room to direct available resources toward PharmaShell development and partner-related activities.

Bears Say

Sharp Revenue DeclineThe sharp TTM revenue contraction indicates that commercial or development income has not yet developed into a stable growth trajectory. Continued volatility makes planning more difficult and weakens confidence that the platform is currently translating into scalable operating revenue.

Persistent Cash BurnSustained operating and free-cash-flow deficits mean Nanexa continues to consume cash to fund its activities rather than supporting them internally. Unless operations improve, ongoing development may require additional financing, which can constrain strategic flexibility over time.

Negative Shareholder ReturnsMeaningfully negative return on equity shows that the company is not yet generating an economic return on shareholders’ capital. Persistent losses can erode the value of invested resources and make future funding or partnership negotiations more important to continued development.

Nanexa AB News

Nanexa AB’s Phase 1 Study on NEX-22A: A Potential Game-Changer for Diabetes Treatment?

Nanexa AB (($DE:40M)) announced an update on their ongoing clinical study. Study Overview: The recent clinical study by...

1y ago

40M

40M FAQ

What was Nanexa AB’s price range in the past 12 months?

Nanexa AB lowest stock price was €0.12 and its highest was €1.28 in the past 12 months.

What is Nanexa AB’s market cap?

Nanexa AB’s market cap is €145.79M.

When is Nanexa AB’s upcoming earnings report date?

Nanexa AB’s upcoming earnings report date is Nov 05, 2026 which is in 34 days.

How were Nanexa AB’s earnings last quarter?

Nanexa AB released its earnings results on Aug 27, 2026. The company reported -€0.007 earnings per share for the quarter.

Is Nanexa AB overvalued?

According to Wall Street analysts Nanexa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanexa AB pay dividends?

Nanexa AB does not currently pay dividends.

What is Nanexa AB’s EPS estimate?

Nanexa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanexa AB have?

Nanexa AB has 164,585,050 shares outstanding.

What happened to Nanexa AB’s price movement after its last earnings report?

Nanexa AB reported an EPS of -€0.007 in its last earnings report. Following the earnings report the stock price went down -3.299%.

Which hedge fund is a major shareholder of Nanexa AB?

Currently, no hedge funds are holding shares in DE:40M

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanexa AB

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.